NCT00767377View on ClinicalTrials.gov

Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC

PHASE2CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

July 31, 2012

Study Completion Date

March 31, 2013

Conditions
Gastric Cancer
Interventions
DRUG

EOF5

epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks

Trial Locations (1)

200032

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT00767377 - Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC | Biotech Hunter | Biotech Hunter